Research programme: nicotinic agonists - Cognetix

Drug Profile

Research programme: nicotinic agonists - Cognetix

Alternative Names: CGX 1204; Nicotinic agonists research programme - Cognetix

Latest Information Update: 29 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Salk Institute; University of Utah
  • Developer Cognetix; Salk Institute; University of Utah
  • Class Peptides; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 20 Jan 2003 This programme is still in active development
  • 19 Jan 2000 Preclinical development for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top